Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Seltorexant versus quetiapine XR adjunctive therapy in major depressive disorder with insomnia symptoms
2020-000341-14Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in major depressive disorder (MDD) comparing Seltorexant adjunctive arm with Quetiapine XR adjunctive comparator arm (2 arms). Primary endpoint: Responder rate at Week 26. Started Jul 2020; status: completed.
02
Drugs
seltorexantquetiapine
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2020-000341-14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000341-14.